Physician profile
Kristen E Hebert
NPI 1093268963
$27,379.63
in general payments reported to CMS, 2019-2025
35 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,472 · 2022: $3,764 · 2023: $5,535 · 2024: $4,124 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,050 · Consulting Fee: $2,038 · Education: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,620.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,050.00 |
| Consulting Fee | $2,037.50 |
| Education | $435.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $8,158.95 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Abbvie INC. | $3,421.44 | 2021-2025 | |
| Leo Pharma INC. | $1,967.20 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $1,460.83 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $1,407.35 | 2021-2025 | Odomzo, Blu-U |
| Ucb, INC. | $1,324.24 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,068.32 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $1,066.74 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $970.51 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $934.51 | 2021-2025 | |
| Amgen INC. | $826.29 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $677.08 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $665.27 | 2022-2025 | Sotyktu, Sprycel |
| Arcutis Biotherapeutics, INC. | $645.51 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $469.36 | 2021-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $421.24 | 2022-2023 | Vtama |
| Almirall LLC | $414.93 | 2021-2025 | Klisyri, Seysara |
| Merz North America, INC. | $288.88 | 2023-2025 | Xeomin |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $234.40 | 2021-2024 | Siliq, Targretin, Arazlo |
| Mayne Pharma Commercial LLC | $179.92 | 2022-2024 | |
| Organon LLC | $153.50 | 2025 | Vtama |
| Genentech USA, INC. | $115.12 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.76 | 2023-2025 | Spevigo |
| Botanix Sb INC | $96.45 | 2025 | Sofdra |
| Allergan, INC. | $92.84 | 2021-2022 | |
| Revance Therapeutics, INC. | $47.48 | 2024 | Daxxify |
| Verrica Pharmaceuticals INC. | $24.47 | 2023 | Ycanth |
| Krystal Biotech INC | $22.28 | 2023 | Vyjuvek |
| Epi Health, LLC | $20.39 | 2021 | |
| Ani Pharmaceuticals, INC. | $18.44 | 2023 | Apexicon E |
| Journey Medical Corporation | $17.21 | 2025 | |
| Boston Scientific Corporation | $15.30 | 2021 | |
| Organogenesis INC. | $13.87 | 2024 | |
| Sanofi-Aventis U.S. LLC | $13.38 | 2021 | |
| Bausch Health US, LLC | $12.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.